KR102740831B1 - 신규 이미다조피리미딘 화합물 및 그의 용도 - Google Patents

신규 이미다조피리미딘 화합물 및 그의 용도 Download PDF

Info

Publication number
KR102740831B1
KR102740831B1 KR1020207016955A KR20207016955A KR102740831B1 KR 102740831 B1 KR102740831 B1 KR 102740831B1 KR 1020207016955 A KR1020207016955 A KR 1020207016955A KR 20207016955 A KR20207016955 A KR 20207016955A KR 102740831 B1 KR102740831 B1 KR 102740831B1
Authority
KR
South Korea
Prior art keywords
alkyl
substituted
unsubstituted
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207016955A
Other languages
English (en)
Korean (ko)
Other versions
KR20200088397A (ko
Inventor
오퍼 레비
데이비드 제이. 다울링
프란체스코 보리엘로
데이비드 에이 스콧
스펜서 이. 브라이트만
프레데릭 페루
Original Assignee
칠드런'즈 메디컬 센터 코포레이션
다나-파버 캔서 인스티튜트 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칠드런'즈 메디컬 센터 코포레이션, 다나-파버 캔서 인스티튜트 인크. filed Critical 칠드런'즈 메디컬 센터 코포레이션
Publication of KR20200088397A publication Critical patent/KR20200088397A/ko
Application granted granted Critical
Publication of KR102740831B1 publication Critical patent/KR102740831B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020207016955A 2017-11-14 2018-11-14 신규 이미다조피리미딘 화합물 및 그의 용도 Active KR102740831B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762586124P 2017-11-14 2017-11-14
US62/586,124 2017-11-14
PCT/US2018/061117 WO2019099564A1 (en) 2017-11-14 2018-11-14 Novel imidazopyrimidine compounds and uses thereof

Publications (2)

Publication Number Publication Date
KR20200088397A KR20200088397A (ko) 2020-07-22
KR102740831B1 true KR102740831B1 (ko) 2024-12-11

Family

ID=66540372

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207016955A Active KR102740831B1 (ko) 2017-11-14 2018-11-14 신규 이미다조피리미딘 화합물 및 그의 용도

Country Status (6)

Country Link
US (1) US11673891B2 (https=)
EP (1) EP3709998B8 (https=)
JP (1) JP7304855B2 (https=)
KR (1) KR102740831B1 (https=)
CN (1) CN111936136B (https=)
WO (1) WO2019099564A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65914B1 (sr) 2017-04-18 2024-10-31 Lilly Co Eli Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja
EP3710007A4 (en) * 2017-11-14 2021-12-15 Children's Medical Center Corporation USE OF IMIDAZOPYRIMIDINE TO MODULATE HUMAN IMMUNE RESPONSE
KR102740831B1 (ko) 2017-11-14 2024-12-11 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도
CN114585606A (zh) 2019-08-29 2022-06-03 希伯塞尔股份有限公司 抑制perk的化合物
WO2021231784A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibiting imidazolopyrazine compounds
WO2024151501A1 (en) * 2023-01-09 2024-07-18 The Children's Medical Center Corporation Novel imidazopyrimidine compound and uses thereof
WO2025151620A1 (en) * 2024-01-10 2025-07-17 The Children's Medical Center Corporation Functionalized imidazopyrimidine compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053915A1 (en) * 2007-12-14 2011-03-03 Alla Chem, Llc HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM
JP2012211149A (ja) * 2005-08-04 2012-11-01 Sirtris Pharmaceuticals Inc サーチュインモジュレーターとしてのベンゾチアゾールおよびチアゾロピリジン
WO2014151784A1 (en) * 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
JP2015526412A (ja) * 2012-07-19 2015-09-10 南京インパクト薬業有限会社Ｉｍｐａｃｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヘッジホッグ経路阻害剤としてのｎ−（３−ヘテロアリールアリール）−４−アリールアリールカルボキサミド及び類似体並びにそれらの使用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69524598T2 (de) 1994-06-20 2002-07-11 Takeda Chemical Industries, Ltd. Kondensierte imidazolderivate, ihre herstellung und verwendung
ES2237470T3 (es) * 1999-11-10 2005-08-01 Ortho-Mcneil Pharmaceutical, Inc. 2-aril-3-(heteroaril)-imidazo(1,2-alfa)pirimidinas sustituidas; y composiciones farmaceuticas y procedimientos asociados.
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
EP1294723A1 (en) 2000-05-24 2003-03-26 MERCK SHARP & DOHME LTD. 3-phenyl-imidazo-pyrimidine derivatives as ligands for gaba receptors
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
ES2328047T3 (es) 2004-03-19 2009-11-06 Warner-Lambert Company Llc Derivados de imidazopiridina e imidazopirimidina como agentes antibacterianos.
BRPI0513811A (pt) 2004-07-27 2008-07-15 Gilead Sciences Inc imidazo [4,5-d] pirimidinas, seus usos e processos de preparação
US20080193468A1 (en) 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1955077B1 (en) * 2005-12-02 2012-06-13 Sirtris Pharmaceuticals, Inc. Mass spectrometry assays for acetyltransferase/deacetylase activity
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
RS54510B1 (sr) 2006-11-22 2016-06-30 Incyte Holdings Corporation Imidazotriazini i imidazopirimidini kao inhibitori kinaze
EP2103614A1 (en) 2008-03-18 2009-09-23 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
FR2933982A1 (fr) 2008-07-18 2010-01-22 Sanofi Aventis Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
JP5694345B2 (ja) 2009-10-22 2015-04-01 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体の調節因子
TWI617559B (zh) * 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
JP6356160B2 (ja) 2013-02-25 2018-07-11 ザ スクリプス リサーチ インスティテュート ネオセプチン：低分子アジュバント
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
CN103467590B (zh) 2013-09-02 2016-04-13 深圳大学 生物偶联体、制备其的嘌呤类化合物、合成方法、药用制剂以及其在免疫调节中的应用
GB201321736D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US10821175B2 (en) 2014-02-25 2020-11-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
BR112016026951B1 (pt) 2014-06-25 2022-09-20 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pirazin-1-il-benzamida, seu uso, e composições farmacêuticas
TW201643143A (zh) 2015-03-13 2016-12-16 國立大學法人北海道大學 抑制氧化壓迫引發的神經細胞死亡之化合物
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
KR102740831B1 (ko) 2017-11-14 2024-12-11 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도
EP3710007A4 (en) 2017-11-14 2021-12-15 Children's Medical Center Corporation USE OF IMIDAZOPYRIMIDINE TO MODULATE HUMAN IMMUNE RESPONSE

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012211149A (ja) * 2005-08-04 2012-11-01 Sirtris Pharmaceuticals Inc サーチュインモジュレーターとしてのベンゾチアゾールおよびチアゾロピリジン
US20110053915A1 (en) * 2007-12-14 2011-03-03 Alla Chem, Llc HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM
JP2015526412A (ja) * 2012-07-19 2015-09-10 南京インパクト薬業有限会社Ｉｍｐａｃｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヘッジホッグ経路阻害剤としてのｎ−（３−ヘテロアリールアリール）−４−アリールアリールカルボキサミド及び類似体並びにそれらの使用
WO2014151784A1 (en) * 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases

Also Published As

Publication number Publication date
CN111936136B (zh) 2024-07-05
WO2019099564A8 (en) 2019-06-27
EP3709998B1 (en) 2024-08-14
JP7304855B2 (ja) 2023-07-07
US20220242867A1 (en) 2022-08-04
EP3709998B8 (en) 2025-02-19
WO2019099564A1 (en) 2019-05-23
KR20200088397A (ko) 2020-07-22
JP2021502986A (ja) 2021-02-04
EP3709998A4 (en) 2021-07-07
US11673891B2 (en) 2023-06-13
EP3709998A1 (en) 2020-09-23
CN111936136A (zh) 2020-11-13

Similar Documents

Publication Publication Date Title
KR102740831B1 (ko) 신규 이미다조피리미딘 화합물 및 그의 용도
US10975055B2 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
US20220227734A1 (en) Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof
US12564591B2 (en) HCK as a therapeutic target in MYD88 mutated diseases
US20250325659A1 (en) Use of toll-like receptor 2 (tlr-2) agonist for modulating human immune response
US20220372017A1 (en) Hck degraders and uses thereof
US20200330449A1 (en) 4(1h)-quinolone derivatives and uses thereof
JP2023175686A (ja) ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用
EP3416950A1 (en) Max binders as myc modulators and uses thereof
JP7821573B2 (ja) Ｄｏｔ１ｌディグレーダーおよびその使用
US20230382865A1 (en) Histone demethylase 5 inhibitors and uses thereof
US9714265B2 (en) Mutagenic nucleoside analogs and uses thereof
US12611456B2 (en) Use of thiazole amide compounds for modulating human immune response
WO2025151620A1 (en) Functionalized imidazopyrimidine compounds and uses thereof
JP2018538364A (ja) ポリアミンスルホンアミドおよびこれらの使用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601